Cannabics Pharmaceuticals, an emerging domestic drug development company
with R&D facilities in Israel, which is focused primarily on
cannabinoid-based therapies like their flagship product, Cannabics SR, a
long-lasting palliative care formulation targeted chiefly at cancer patients,
continues expanding its presence in the booming U.S. medical marijuana (MMJ)
market. News last month in mid-December that the company has secured engagement
in Colorado with Mountain High Products for the manufacturing and distribution
of the Cannabics SR extended-release product, comes at an auspicious time, as
MMJ retail sales have ballooned to around $300M for the year in Colorado, doing
about $32M a month as of late 2014.
Cannabics SR is an ideal product for states like Minnesota and New York,
where the recently passed MMJ laws only allow for a 30-day supply of
non-smokeable MMJ. Growing receptivity within the medical community and among
patients alike has led to unprecedented demand for MMJ to treat a variety of
conditions that can be addressed via the increasingly well understood therapeutic
properties of cannabinoids. Moreover, many of the conditions for which MMJ is
now being prescribed have historically been treated with comparatively more
potentially dangerous or habit-forming pharmaceuticals, like opioid
derivatives. Consumers are now turning to MMJ for even everyday aches and pains
in some cases, seeing MMJ as a relatively benign alternative to the possibly
severe and sometimes fatal gastrointestinal bleeding associated with
over-the-counter NSAIDs (nonsteroidal anti-inflammatory drugs), especially in
chronic pain use cases.
Additionally, an oral capsule formulation of cannabinoids, like Cannabics
SR, elegantly sidesteps the stigma and potential risks of smoking or vaporizing
that many patients dislike, with the added benefit that both elderly and child
patients who cannot smoke, are also able to access the therapeutic benefits
that such a product has to offer. With the recent landmark FDA approval of a
clinical study of cannabidiol (CBD, a non-psychoactive component extracted from
cannabis) in childhood epilepsy and a growing number of such studies into the
broad-spectrum pain relief, mood elevating and neurological normalizing
functions of cannabinoids, the iron is red-hot for a commercial, proprietary
formulation that takes advantage of the increasingly promising pharmacokinetics
of THC (the psychoactive component of cannabis) and CBD.
Cannabics SR capsules are perfect for patients who are new to MMJ and
represent a safe, standardized dosage (10mg of active cannabinoids) that is
easy to administer. Unlike most edibles, the amount of THC and the formulation
thereof is controlled with Cannabics SR, making the product attractive to new
patients, or patients who want to avoid the potentially deleterious
psychotropic side effects of a large, unmeasured dosage as is common among edible
forms of MMJ.
Comprised of pure, concentrated extracts of carefully selected cannabis
strains, Cannabics SR capsules are also completely free of any artificial
additives or chemical substances and can easily be double or tripled dosed to
achieve therapeutic windows of 8 to 12 (20mg), or 12 to 18 hours (30mg). While
it is never recommended for new patients to start a regimen at dosages over
10mg, observational studies have shown a single dose can provide up to 10 to 12
hours of steady-state therapeutic effect on its own, and the rapid onset (20 to
60 minutes) with sustained beneficial effects that is achievable with this
formulation, makes the product perfect for once, or twice-daily dosing. It is
not unthinkable that such a product could gradually emerge as the standard
alternative or companion to common over-the-counter pain medications, as state
regulators continue to roll back antiquated restrictions on marijuana.
With nationwide MMJ revenues for 2014 around $2B on only 23 states and DC
having created new laws to legalize it, the increasingly inescapable attraction
of associated tax revenues for state legislators, like the $7.6M added to
Colorado’s state coffers in October 2014, will no doubt continue to put
pressure on the remaining states to reform. The future of the market for
cannabinoid-based therapy products like Cannabics SR looks solid, but the
company isn’t content to rest solely on the laurels of their superb cannabinoid
formulation, they are hard at work applying their combined and extensive
experience in molecular biology, cancer research and pharmacology to advancing
new advanced drugs and therapies, as well as food supplements based on the
considerably vast diversity of strains of the cannabis plant.
Learn more about Cannabics Pharmaceuticals by visiting www.cannabics.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that
have huge potential to succeed in the short and long-term future. We offer
several ways for investors to find, evaluate, and learn more about investing in
these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment